

**Quinazoline derivatives.**

Patent Number: EP0566226

Publication  
date:

1993-10-20

Inventor(s): BARKER ANDREW JOHN (GB)

Applicant(s):: ZENECA LTD (GB)

Requested  
Patent:☐ EP0566226, B1Application  
Number:

EP19930300270 19930115

Priority Number  
(s):

GB19920001095 19920120; GB19920013572 19920626; GB19920023735 19921112

IPC

Classification: C07D239/94 ; C07D491/056 ; C07D403/12 ; A61K31/505

EC

Classification: C07D239/94, C07D403/04, C07D491/04

Equivalents:

AU3101093, AU661533, CA2086968, ☐ CZ282038, DE69300754D, DE69300754T, ES2078798T, FI930208, GR3018143T, HK36497, HU63153, HU9500185, IL104479, KR229294, NO301541B, NZ245662, RU2127263, SK1693**Abstract**

The invention concerns quinazoline derivatives of the formula I wherein m is 1, 2 or 3 and each R<1> includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy; n is 1 or 2 and each R<2> includes hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.

Data supplied from the esp@cenet database - I2

— Please see exhibit 33 —